BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 35681786)

  • 1. New Therapeutic Strategies for Adult Acute Myeloid Leukemia.
    Ishii H; Yano S
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What to use to treat AML: the role of emerging therapies.
    Thol F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
    Yamauchi T
    Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development.
    Stanchina M; Soong D; Zheng-Lin B; Watts JM; Taylor J
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33139625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
    Bazinet A; Assouline S
    Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
    [No Abstract]   [Full Text] [Related]  

  • 8. New Treatment Options for Acute Myeloid Leukemia in 2019.
    Cerrano M; Itzykson R
    Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What is recommended in the treatment of acute myeloid leukemia?].
    Thol F
    Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents.
    Halik A; Arends CM; Bullinger L; Damm F; Frick M
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML: New Drugs but New Challenges.
    Burnett A; Stone R
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New and emerging therapies for acute myeloid leukaemia.
    Davis JR; Benjamin DJ; Jonas BA
    J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapies for acute myeloid leukemia.
    Saygin C; Carraway HE
    J Hematol Oncol; 2017 Apr; 10(1):93. PubMed ID: 28420416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
    Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
    Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
    Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
    Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.